You just read:

Interim Results from Phase 1b/2 Study Evaluating the Combination of Merck's KEYTRUDA® (pembrolizumab) and Eisai's HALAVEN® (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 San Antonio Breast Cancer Symposium

News provided by

Eisai Inc.

Dec 12, 2016, 07:00 ET